Cancer stem cells (CSCs) represent a specialized subset within tumors, endowed with the remarkable ability to self-renew and diversify, thus fueling tumor progression and recurrence. They stand out for their resilience against traditional cancer therapies, surviving treatments that typically eliminate the bulk of tumor cells. CSCs bear resemblance to normal stem cells, exhibiting specific surface markers and the capacity to initiate tumors in experimental models. The pursuit of CSC-targeted therapies holds significant promise in cancer research, aiming to dismantle the foundation of tumor growth and thwart its resurgence. Deciphering the intricacies of CSC biology stands as a pivotal endeavor, potentially paving the way for the development of more potent and enduring treatments against cancer.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China